FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 300 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Healthy 33-Year-Old Nurse Learned She Had Cervical Cancer and Breast Cancer... April 30, 2019 Appendix Cancers Are Genetically Distinct from Other Gastrointestinal Cancers, Study Shows September 12, 2018 England slips further off-track for smokefree 2030 target December 29, 2022 Animal Shelters Are Honoring Healthcare Workers By Naming Shelter Dogs After... April 22, 2020 Load more HOT NEWS Chemotherapy Administered for the First Diagnosed Testicular Cancer Reduces the Risk... Outcomes of Cancer Patients with SARS-CoV-2 Infection in Veneto FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection Does Too Much Fructose Help Colorectal Cancers Grow?
